Alain P. Algazi

22.6k total citations · 1 hit paper
113 papers, 4.8k citations indexed

About

Alain P. Algazi is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Alain P. Algazi has authored 113 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 35 papers in Molecular Biology and 23 papers in Immunology. Recurrent topics in Alain P. Algazi's work include Cancer Immunotherapy and Biomarkers (48 papers), Melanoma and MAPK Pathways (27 papers) and CAR-T cell therapy research (19 papers). Alain P. Algazi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (48 papers), Melanoma and MAPK Pathways (27 papers) and CAR-T cell therapy research (19 papers). Alain P. Algazi collaborates with scholars based in United States, Canada and Italy. Alain P. Algazi's co-authors include Kimmo Alho, David L. Woods, Adil Daud, Katy K. Tsai, Risto Näätänen, Robert T. Knight, Risto Näätänen, Susana Ortiz‐Urda, Igor Vujic and Martina Sanlorenzo and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Alain P. Algazi

106 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

2017 300 citations Samuel Ejadi, Caroline Even et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alain P. Algazi United States	32	2.7k	1.3k	1.2k	1.1k	588	113	4.8k
Carolina Gutiérrez United States	24	2.2k 0.8×	1.5k 1.2×	272 0.2×	268 0.2×	486 0.8×	47	3.5k
Daniel M. Ramos United States	29	528 0.2×	1.2k 0.9×	313 0.3×	175 0.2×	140 0.2×	73	2.6k
Atsushi Natsume Japan	42	1.3k 0.5×	2.4k 1.9×	914 0.8×	111 0.1×	504 0.9×	189	5.2k
Sarah A. Weiss United States	21	1.2k 0.4×	512 0.4×	477 0.4×	101 0.1×	405 0.7×	66	2.0k
Rainald Knecht Germany	32	1.5k 0.6×	1.1k 0.9×	178 0.1×	126 0.1×	865 1.5×	154	3.6k
Sandra Costa Portugal	27	668 0.2×	970 0.7×	349 0.3×	247 0.2×	337 0.6×	77	2.3k
Jeffrey M. Conroy United States	31	861 0.3×	1.7k 1.3×	343 0.3×	231 0.2×	479 0.8×	133	3.7k
Christoph Reuter Germany	26	486 0.2×	1.3k 1.0×	122 0.1×	88 0.1×	308 0.5×	106	2.2k
Michael A. Patton United Kingdom	36	597 0.2×	4.1k 3.1×	1.5k 1.2×	82 0.1×	214 0.4×	82	6.0k
F. Koerner Switzerland	20	1.1k 0.4×	899 0.7×	74 0.1×	349 0.3×	228 0.4×	52	2.8k

Countries citing papers authored by Alain P. Algazi

Since Specialization

Citations

This map shows the geographic impact of Alain P. Algazi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain P. Algazi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain P. Algazi more than expected).

Fields of papers citing papers by Alain P. Algazi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alain P. Algazi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain P. Algazi. The network helps show where Alain P. Algazi may publish in the future.

Co-authorship network of co-authors of Alain P. Algazi

This figure shows the co-authorship network connecting the top 25 collaborators of Alain P. Algazi. A scholar is included among the top collaborators of Alain P. Algazi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alain P. Algazi. Alain P. Algazi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Raymond Y., Gilbert Youssef, Patrick Y. Wen, et al.. (2025). Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204. Journal of Clinical Oncology. 43(10). 1210–1218. 2 indexed citations

Algazi, Alain P., James Moon, Christopher D. Lao, et al.. (2024). A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers. Cancer. 130(10). 1784–1796. 6 indexed citations

Algazi, Alain P., Kyriakos P. Papadopoulos, Frank Tsai, et al.. (2024). Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study. ESMO Open. 9(8). 103646–103646. 4 indexed citations

Barker, Christopher A., Suzanne M. Dufault, Sarah T. Arron, et al.. (2024). Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma. Journal of Clinical Oncology. 42(19). 2327–2335. 9 indexed citations

Zhou, Connie J., et al.. (2023). Carboplatin and paclitaxel after anti‐PD‐1 or anti‐PD‐L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck. Head & Neck. 46(2). 321–327. 1 indexed citations

Oh, Do‐Youn, Alain P. Algazi, Jaume Capdevila, et al.. (2023). Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study. Cancer. 129(8). 1195–1204. 31 indexed citations

Gulati, Arushi, Mary Jue Xu, Patrick K. Ha, et al.. (2023). A prospective evaluation of neck and shoulder function following treatments of early‐stage human papillomavirus‐associated oropharynx cancer. Clinical Otolaryngology. 48(5). 756–765. 1 indexed citations

Huang, Raymond Y., Patrick Y. Wen, Peter Forsyth, et al.. (2023). 1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204. Annals of Oncology. 34. S680–S681. 1 indexed citations

Aggarwal, Charu, Nabil F. Saba, Alain P. Algazi, et al.. (2022). Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 29(3). 560–570. 26 indexed citations

10.

Ribas, Antoni, Alain P. Algazi, Paolo A. Ascierto, et al.. (2021). Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications. 12(1). 5022–5022. 1 indexed citations

11.

Ribas, Antoni, Alain P. Algazi, Paolo A. Ascierto, et al.. (2020). PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications. 11(1). 60 indexed citations

12.

Aggarwal, Charu, Nabil F. Saba, Alain P. Algazi, et al.. (2020). 916MO Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC). Annals of Oncology. 31. S661–S662. 16 indexed citations

13.

Harrington, Kevin J., William N. William, Anuradha Khilnani, & Alain P. Algazi. (2020). 972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma. Annals of Oncology. 31. S683–S683. 8 indexed citations

14.

Babiker, Hani M., Erkut Borazanci, Vivek Subbiah, et al.. (2020). 1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours. Annals of Oncology. 31. S711–S712. 2 indexed citations

15.

Algazi, Alain P., Katy K. Tsai, Lawrence R. Chen, et al.. (2019). Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunology Research. 8(2). 246–254. 68 indexed citations

16.

Zandberg, Dan P., Alain P. Algazi, Antonio Jimeno, et al.. (2017). Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study. Annals of Oncology. 28. v372–v372. 24 indexed citations

17.

Algazi, Alain P., Katy K. Tsai, Alexander N. Shoushtari, et al.. (2016). Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies. Cancer. 122(21). 3344–3353. 265 indexed citations

18.

Rosen, Lee S., Jonathan W. Goldman, Alain P. Algazi, et al.. (2016). A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clinical Cancer Research. 23(8). 1910–1919. 57 indexed citations

19.

Hsu, Chih‐Hung, Seung‐Hoon Lee, Samuel Ejadi, et al.. (2015). 315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Annals of Oncology. 26. ix93–ix93. 13 indexed citations

20.

Comı́n-Anduix, Begoña, Jason Jalil, Alain P. Algazi, et al.. (2008). Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. Journal of Translational Medicine. 6(1). 22–22. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact